LGD-4033 (Ligandrol (LGD-4033))

Category: Muscle Growth. Status: Investigational.

A non-steroidal SARM with high affinity for muscle and bone tissue. One of the most researched SARMs with demonstrated lean mass gains.

How it works

Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity.

Key facts

• Molecular weight: 338.25 Da
• Half-life: ~24-36 hours
• Bioavailability: ~90% oral
• Storage: Room temperature, protect from moisture and light.

Dosing overview

• Typical dose: 5-10 mg
• Frequency: Once daily
• Duration: 6-8 weeks
• Route: Oral

Reported benefits

• Significant lean mass gains
• Bone density improvement
• Oral convenience
• Selective tissue activity

Possible side effects

• Testosterone suppression
• Mild headache
• Water retention
• Fatigue

Research

• LGD-4033 Phase 1 dose escalation (2013): Dose-dependent lean mass increases (1.21kg at 1mg/day) over 21 days with reversibility.
• SARMs for muscle wasting (2020): Preserved lean mass in cancer cachexia without prostate stimulation.

Compare LGD-4033

• LGD-4033 vs Follistatin 344
• LGD-4033 vs ACE-031
• LGD-4033 vs IGF-1 LR3
• LGD-4033 vs MGF (Mechano Growth Factor)
• LGD-4033 vs Myostatin Inhibitor
• LGD-4033 vs YK-11

Community discussions about LGD-4033

• First time with LGD-4033 – protocol, dosing, and reconstitution basics? - 4 comments
• Ask the community about LGD-4033

Research and educational reference only. Not medical advice.